Survival 79 Percent for Congenital Diaphragmatic Hernia

This article originally appeared here.
Share this content:
Survival 79 Percent for Congenital Diaphragmatic Hernia
Survival 79 Percent for Congenital Diaphragmatic Hernia

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Survival is 79 percent for neonates with congenital diaphragmatic hernia (CDH) undergoing surgical repair, with higher survival for those not needing extracorporeal membrane oxygenation (ECMO), according to a study published online Feb. 17 in Pediatric Anesthesia.

Katarina Bojanic, M.D., from the University Hospital Merkur in Zagreb, Croatia, and colleagues performed a retrospective cohort study involving consecutive neonates treated for CDH from 2001 to 2015. Hospital and post-discharge data were reviewed for neonatal, disease, and treatment characteristics for 38 neonates admitted during the study period.

Life support was withdrawn for three neonates who were in extremis. The researchers found that the other 35 neonates underwent surgical repair and eight received ECMO. The overall survival was 79 percent; survival was 89 percent among those who had surgical correction but did not need ECMO, and 75 percent for those who received ECMO and had surgery. Lower hospital survival was seen for liver-up versus liver-down CDH (61 versus 95 percent; odds ratio, 0.08). The median duration of hospitalization was 31 days among survivors. The most noted comorbid conditions after discharge were major chronic pulmonary and gastrointestinal disorders, failure to thrive, and neurodevelopmental delays; these were all more prevalent among neonates requiring ECMO.

"The overall survival of neonates with CDH was 79 percent," the authors write. "A substantial number of survivors, especially those who required ECMO, experienced chronic conditions after discharge."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »